Loading candles…
Bal Pharma Ltd, incorporated in 1987, operates in the pharmaceutical industry with a focus on manufacturing and marketing active pharmaceutical ingredients (APIs), finished formulations, and specialty products. The company produces pharmaceutical products including APIs, generic drugs, specialty drugs, and finished formulations. Bal Pharma serves multiple therapeutic segments such as anti-diabetics, anti-infectives, and gastroenterology, catering to both domestic and international markets. The company concentrates on developing a pipeline of generic and specialty drugs while managing a diverse portfolio to address various healthcare needs globally.
This page is a live market overview for BAL PHARMA LTD. (BALPHARMA) on the NSE. As a listed security, BAL PHARMA LTD. is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for BALPHARMA before placing trades on tick2trade.
As of the latest feed, BALPHARMA last traded at ₹89.23 on NSE, up ₹2.34 (2.69%) from the previous close of ₹86.89. Today's session range is ₹86.97 – ₹89.59, against a 52-week band of ₹60 – ₹98.85. Traded volume today stands at 14.26K shares.
The overview consolidates an interactive price chart with multiple time ranges, upcoming corporate events for BALPHARMA in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether BALPHARMA is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for BAL PHARMA LTD. before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in BALPHARMA. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated BALPHARMA option chain page linked from this overview.
| Results - FY25 |
| To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters |
| 11 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025, dividend and other business matters | 29 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.